These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16546667)

  • 41. Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death.
    Maiti K; Oh DY; Moon JS; Acharjee S; Li JH; Bai DG; Park HS; Lee K; Lee YC; Jung NC; Kim K; Vaudry H; Kwon HB; Seong JY
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4287-98. PubMed ID: 15870130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
    Zhang X; Li W; Olumi AF
    Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
    Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
    Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Yoo J; Lee YJ
    Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A clinician's guide to the use of gonadotropin-releasing hormone analogues in women.
    Moghissi KS
    Medscape Womens Health; 2000 Jan; 5(1):5. PubMed ID: 10792849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of PER1 mRNA expression in immortalized gonadotropes by gonadotropin-releasing hormone (GnRH): involvement of protein kinase C and MAP kinase signaling.
    Olcese J; Sikes HE; Resuehr D
    Chronobiol Int; 2006; 23(1-2):143-50. PubMed ID: 16687288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone.
    Enomoto M; Seong JY; Kawashima S; Park MK
    Life Sci; 2004 May; 74(25):3141-52. PubMed ID: 15081579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GnRH signaling in intrauterine tissues.
    Wu HM; Wang HS; Huang HY; Soong YK; MacCalman CD; Leung PC
    Reproduction; 2009 May; 137(5):769-77. PubMed ID: 19208750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways.
    Uzgare AR; Isaacs JT
    Int J Biochem Cell Biol; 2005 Apr; 37(4):707-14. PubMed ID: 15694830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence for hormone-responsive cleavage of gonadotropin-releasing hormone by the plasma membrane of ovarian cancer cells.
    Imai A; Iida K; Furui T; Tamaya T
    Int J Oncol; 2002 May; 20(5):987-92. PubMed ID: 11956594
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [GnRH analogs in gynecology. Possibilities for therapeutic use].
    Niesert S
    Fortschr Med; 1990 Sep; 108(26):498-500. PubMed ID: 2262188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?
    Montagnani Marelli M; Moretti RM; Januszkiewicz-Caulier J; Motta M; Limonta P
    Curr Cancer Drug Targets; 2006 May; 6(3):257-69. PubMed ID: 16712461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy Insight: osteoporosis during hormone therapy for prostate cancer.
    Smith MR
    Nat Clin Pract Urol; 2005 Dec; 2(12):608-15; quiz 628. PubMed ID: 16474548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs.
    Pappa EV; Zompra AA; Spyranti Z; Diamantopoulou Z; Pairas G; Lamari FN; Katsoris P; Spyroulias GA; Cordopatis P
    Biopolymers; 2011; 96(3):260-72. PubMed ID: 20632397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma.
    Szabó J; Végh A; Rácz G; Szende B
    Urol Oncol; 2005; 23(6):399-401. PubMed ID: 16301116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pituitary gonadotropin releasing hormone (GnRH) and breast cancer].
    Vargas Hernández VM; Moctezuma Espinosa J
    Ginecol Obstet Mex; 1995 Dec; 63():493-6. PubMed ID: 8586292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.